Compare Davita Inc (DVA) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Payoneer Global Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Payoneer Global Inc trades at $7.19 (market cap $2.43B). The key difference: Davita Inc is far larger — about 4.6× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Payoneer Global Inc for 61 Days on average.
| DVA | PAYO | |
|---|---|---|
Market Cap | $11.28B | $2.43B |
Volume | 650,294 | 1,601,413 |
Sector | Health | Technology |
52-Week High | $240.96 | $7.18 |
52-Week Low | $103.87 | $4.27 |
Typical Hold Time | 113 Days | 61 Days |
Enterprise Value | $24.00B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Payoneer Global (PAYO) trades at $7.16, up 0.14% with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q2 2026. Revenue grew to $821M in 2025, though net income margin compressed to 5.83%. Recent news highlights Payoneer's renewed partnership with Etsy through 2029 and a pending acquisition by Nuvei announced in June 2026.
The outlook is clouded by earnings volatility and acquisition uncertainty, but analyst sentiment remains positive with 60% buy ratings. Key risks include integration challenges post-acquisition and competitive pressures in fintech. The stock's elevated P/E of 51.14 suggests growth expectations must materialize to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
